Bavarian Nordic is committed to building a pipeline of immunotherapy candidates for major cancers with large unmet medical needs. The Company leverages its viral vaccine platforms to create novel, non-patient specific immunotherapy candidates to efficiently target and kill cancer cells while sparing the surrounding tissue, which is critical in the treatment process.
Targeted active immunotherapy candidates for the treatment of cancer are part of a promising field of research, which harnesses the power of the immune system to fight cancer. By eliciting a robust and broad anticancer immune response, immunotherapies aim to decrease the tumor growth rate, potentially resulting in a prolonged overall survival while maintaining a favorable risk-benefit profile.
The Company’s lead development candidate, PROSTVAC®, is currently in a Phase 3 pivotal trial.